Y-mAbs Therapeutics, Inc. (YMAB) Financial Statements
Y-mAbs Therapeutics, Inc. (YMAB) files with the U.S. Securities and Exchange Commission under CIK 0001722964. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2024
- Revenue
- $87.69 million
- Net Income
- -$29.67 million
- Total Assets
- $119.90 million
- Net Cash from Operations
- -$15.71 million
Fiscal year ended Dec 31, 2024. Latest periodic SEC filing: Aug 8, 2025. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for YMAB in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History